Inhibitory activity of prostaglandin E2 production by the synthetic 2′-hydroxychalcone analogues: Synthesis and SAR study

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 6, 2009, Pages 1650-1653

  Tran, Thanh Dao ^a   Park, Haeil ^b   Kim, Hyun Pyo ^b   Ecker, Gerhard F ^c   Thai, Khac Minh ^a  

^a UNIVERSITY OF MEDICINE AND PHARMACY AT HO CHI MINH CITY   (Viet Nam)

^b Kangwon National University   (South Korea)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

Anti inflammation; Chalcone; COX 2; Cytotoxicity; PGE2

Indexed keywords

2' HYDROXY 3,4,5 TRIMETHOXYCHALCONE; 2' HYDROXYCHALCONE DERIVATIVE; 2,3 DIMETHOXY 2' HYDROXYCHALCONE; 2,4 DIMETHOXY 2' HYDROXYCHALCONE; 3 BENZYLOXY 4 METHOXY 2' HYDROXYCHALCONE; 3,4 DIBENZYLOXY 2' HYDROXYCHALCONE; 3,4,5 TRIMETHOXY 2' HYDROXYCHALCONE; 4 BENZYLOXY 2' HYDROXYCHALCONE; CHALCONE DERIVATIVE; CYCLOOXYGENASE 2; PROSTAGLANDIN E2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG SYNTHESIS; MOLECULAR DOCKING; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; CELL LINE; CHALCONE; CHALCONES; CHEMISTRY, PHARMACEUTICAL; CYCLOOXYGENASE 2; DINOPROSTONE; DRUG DESIGN; INFLAMMATION; INHIBITORY CONCENTRATION 50; LIPOPOLYSACCHARIDES; MICE; MODELS, CHEMICAL; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS;

EID: 61649095702     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.02.001     Document Type: Article

References (31)

1. Barnard D.L., Smee D.F., Huffman J.H., Meyerson L.R., and Sidwell R.W. Chemotherapy 39 (1993) 203
2. De Meyer N., Haemers A., Mishra L., Pandey H.K., Pieters L.A., Vanden Berghe D.A., and Vlietinck A.J. J. Med. Chem. 34 (1991) 736
3. Won S.J., Liu C.T., Tsao L.T., Weng J.R., Ko H.H., Wang J.P., and Lin C.N. Eur. J. Med. Chem. 40 (2005) 103
4. Cabrera M., Simoens M., Falchi G., Lavaggi M.L., Piro O.E., Castellano E.E., Vidal A., Azqueta A., Monge A., de Ceráin A.L., Sagrera G., Seoane G., Cerecetto H., and González M. Bioorg. Med. Chem. 15 (2007) 3356
5. Formento-Navarini, A. L.; Chiaradia, L. D.; Mascarello, A.; Fritzen, M.; Nunes, R. J.; Yunes, R. A.; Creczynski-Pasa, T. B. Eur. J. Med. Chem., in press. doi: 10.1016/j.ejmech.2008.09.009.
6. Vogel S., Ohmayer S., Brunner G., and Heilmann J. Bioorg. Med. Chem. 16 (2008) 4286
7. Vogel S., and Heilmann J. J. Nat. Prod. 71 (2008) 1237
8. Alam S., and Mostahar S. J. Appl. Sci. 5 (2005) 327
9. Ohemeng K.A., Schwender C.F., Fu K.P., and Barrett J.F. Bioorg. Med. Chem. Lett. 3 (1993) 225
10. Alcaraz M.J., and Jimenez M.J. Fitoterapia 59 (1988) 25
11. Arockia Babu M., Shakya N., Prathipati P., Kaskhedikar S.G., and Saxena A.K. Bioorg. Med. Chem. 10 (2002) 4035
12. Kim Y.H., Kim J., Park H., and Kim H.P. Biol. Pharm. Bull. 30 (2007) 1450
13. Capasso A., Pinto A., Mascolo N., Autore G., and Capasso F. Phytother. Res. 5 (1991) 85-87
14. Dao T.T., Chi Y.S., Kim J., Kim H.P., Kim S., and Park H. Bioorg. Med. Chem. Lett. 14 (2004) 1165
15. Chiaradia L.D., dos Santos R., Vitor C.E., Vieira A.A., Leal P.C., Nunes R.J., Calixto J.B., and Yunes R.A. Bioorg. Med. Chem. 16 (2008) 658
16. Suzuki K., Hyun Seung B., Soon Sung L., Sanghyun L., Sang Hoon J., Yeon Sil L., Kuk Hyun S., and Ohuchi K. Ensho Saisei 25 (2005) 130
17. Gomes A., Fernandes E., Lima J.L., Mira L., and Corvo M.L. Curr. Med. Chem. 15 (2008) 1586
18. Ram V.J., Saxena A.S., Srivastava S., and Chandra S. Bioorg. Med. Chem. Lett. 10 (2000) 2159
19. Nielsen S.F., Christensen S.B., Cruciani G., Kharazmi A., and Liljefors T. J. Med. Chem. 41 (1998) 4819
20. Corréa R., Pereira M.A.S., Buffon D., dos Santos L., Cechinel-Filho V., Santos A.R.S., and Nunes R.J. Arch. Pharm. Med. Chem. 334 (2001) 332
21. Daskiewicz J.B., Depeint F., Viornery L., Bayet C., Comte-Sarrazin G., Comte G., Gee J.M., Johnson I.T., Ndjoko K., Hostettmann K., and Barron D. J. Med. Chem. 48 (2005) 2790
22. 2) to give the product.
23. +, 70), 308 (100), 307 (95), 188 (68), 147 (94), 121 (94), 120 (96), 101 (70).
24. 3) C, H, O.
25. Chi Y.S., Cheon B.S., and Kim H.P. Biochem. Pharmacol. 61 (2001) 1195
26. 2 according to the manufacturer's recommendation. All experiments were carried out at least three times.
27. Han K.H., Son M.J., Chang H.W., Chi Y.S., Park H., and Kim H.P. Biol. Pharm. Bull. 28 (2005) 1366
28. Molecular Operating Environment MOE, Chemical Computing Group Inc., Montreal, H3A 2R7 Canada. http://www.chemcomp.com.
29. -1. The lowest-energy conformer of each molecule was selected and stored in mdb database. Preparation of target enzyme structure and docking. The X-ray crystal structure of COX-2:SC-558 complex (pdb 1cx2) was retrieved from the RCSB Protein Data Bank (www.rcsb.org). The active site was defined as all the amino acid residues enclosed within 6.5 Å radius sphere centered by the bound ligand, SC-558 (1-phenylsulfonamied-3-trifluoromethyl-5-parabromophenyl-pyrazole, a selective COX-2 inhibitor) and 'site finder' in MOE was used to determine the binding site. The docking and subsequent scoring were performed using the MOE docking programs. The final of 30 docked conformations per ligand were analyzed and used to create the illustrative figures.
30. Mossman T. J. Immunol. Methods 65 (1983) 55
31. Cho H., Yun C.-W., Park W.-K., Kong J.-Y., Kim K.S., Park Y., Lee S., and Kim B.-K. Pharmacol. Res. 49 (2004) 37